|

The Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder

RECRUITINGN/ASponsored by Shanghai Mental Health Center
Actively Recruiting
PhaseN/A
SponsorShanghai Mental Health Center
Started2025-08
Est. completion2027-06
Eligibility
Age18 Years – 50 Years
Healthy vol.Accepted

Summary

This study aims to evaluate the efficacy of Temporal Interference (TI) stimulation in treating patients with obsessive-compulsive disorder (OCD) and to explore its potential neural mechanisms using magnetic resonance imaging (MRI) and electroencephalography (EEG).

Eligibility

Age: 18 Years – 50 YearsHealthy volunteers accepted
Inclusion Criteria:

* 18-50 years old
* Diagnosis of OCD per DSM-5
* Y-BOCS score ≥20
* Have a documented history of at least two adequate trials of selective serotonin reuptake inhibitors (SSRIs). If currently receiving SSRI treatment, the dosage must be stable for at least 8 weeks prior to enrollment
* With at least 9 years of education

Exclusion Criteria:

* Any DSM-5 diagnosis other than OCD (except OCPD)
* OCD symptoms too severe to complete assessments
* Received electroconvulsive therapy (ECT) within the past 6 months
* Received other forms of neuromodulation within the past 2 months(see Item 3 for ECT)
* Severe medical illness or seizure risk (e.g., cardiovascular, respiratory conditions)
* Neurological disorders or history of brain injury/surgery
* MRI-incompatible implants (e.g., pacemaker, stents, cochlear implants).
* Current suicidal risk per investigator judgment
* Pregnant or planning pregnancy during the study
* Started structured OCD psychotherapy within 3 months, with expected change during treatment

Conditions2

AnxietyObsessive Compulsive Disorder (OCD)

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.